Feedback Share Discussion Threads

[ged5] 08/11/2019 12:28

I guess the volume is too low for any meaningful chart analysis but the recent movement in the Williams indicator would suggest there's some momentum building.

I can't see it myself but just interested to see what happens.

[ducatiman] 08/11/2019 12:09

Let's see what next year brings

[ged5] 08/11/2019 09:17

Post 3925
Let's see what this week brings.
Post 3934
Correct!

[sonie01] 07/11/2019 13:34

What's happening with this one?

[sonie01] 06/11/2019 14:30

Sammy unless you back up with quality research, quite frankly get lost

[sammyshares] 06/11/2019 12:47

Caution needed.

[ducatiman] 04/11/2019 19:06

Transfer, rollover. Nothing to get excited about.

[lr2] 04/11/2019 18:53

Looks like a transfer. No idea what.

[seppin] 04/11/2019 18:45

Transfers LR2? SIPP?

[lr2] 04/11/2019 18:31

Late trades tonight. Big 'uns.

01-Nov-19 15:51:01 1.05p 4,500,000 Sell* 1.05 1.15 47.25k
01-Nov-19 15:50:51 1.0493p 4,500,000 Sell* 1.05 1.15 47.22k

[sammyshares] 04/11/2019 09:39

Caution needed.

[ged5] 04/11/2019 08:40

Let's see what this week brings.
They soon raised the offer.

[sammyshares] 03/11/2019 22:13

It will end down.

[lr2] 03/11/2019 16:08

RSNA 2019 - 105th Scientific Assembly and General Meeting
December 1-6, McCormick Place, Chicago

SSQ10-04 CT Texture Predicts Metastatic RCC Response to Anti-Angiogenic Therapy
Thursday, Dec. 5 11:00AM - 11:10AM Room: E352

Page 144.

Antoine Saillant, Somerset, United Kingdom (Abstract Co-Author) Employee, Feedback PLC
Balaji Ganeshan, PhD, London, United Kingdom (Abstract Co-Author) Research partner & Director, Feedback Medical Ltd; Research partner & CEO, TexRAD Ltd; Director, Stone Checker Software Ltd;



PURPOSE

The objective of this study was to quantify initial changes in CT texture to predict progression-free survival (PFS) in patients with metastatic renal cell carcinoma (RCC) treated with anti-angiogenic therapy.

METHOD AND MATERIALS

For this retrospective post-hoc secondary analysis of a prospective phase III trial, adult patients with metastatic RCC treated with sunitinib were included (N=275). Up to 5 target lesions were segmented using freeform regions-of-interest on 2D axial images on the baseline and initial post-therapy CT studies using eMASS software (eMASS LLC, Hoover, AL), to derive change in tumor length and vascular tumor burden (VTB). The segmentations were then processed using TexRAD software (Feedback Medical Ltd., Cambridge, UK) which used a CT texture filtration-histogram technique. A total of 6 texture parameters were measured at 6 filtration levels for a total of 36 texture/filtration parameters. Initial changes in CT texture were associated with PFS using univariate Kaplan Meier survival analysis (log-rank test). Multivariate Cox-proportional analysis was used to assess the independence of CT texture from other imaging biomarkers.

[ged5] 03/11/2019 13:54

For anyone who is interested I received a reply to the letter I posted in 3765. I was assured that The DPA 1998 along with the new legislation of 2018 would be enough to have our data protected.

I wonder how many people within the London NHS Trust knew their data was going to DeepMind and now to Google. I also wonder how many patients within the Taunton and Somerset Trusts know their data will be heading for Google computers.

I won't be following up on this point to my MP who will probably not be re-elected since he completely avoided the main point of data being sent abroad when there is a perfectly acceptable means of storage and confidentiality in Feedback's products.

Here is the relevant article again:-

[ged5] 03/11/2019 12:11

I've just seen the link and was thinking the very same thing.

Makes a point that the main body of the Board are new, Prof Shaw and Dr Oakley and that the Board will strive to act in accordance with the QCA code.

[seppin] 03/11/2019 12:01

I wonder LR2 if the update is a response to recent exchanges with shareholders? It would be reassuring if they have been listening.

[ged5] 03/11/2019 12:00

LOL. It take all sorts.

[lr2] 03/11/2019 10:56

Oh, those are just traders closing positions from earlier in the week. Both lost money.

29-Oct-19 09:05:08 1.047p 440,691 Buy

30-Oct-19 09:27:34 1.025p 156,557 Buy
30-Oct-19 09:26:56 1.023p 250,000 Buy

[ged5] 03/11/2019 10:39

Thanks LR2.

14:51:07 440691 at .9951p
14:51:12 406557 at 1p

[lr2] 03/11/2019 10:35

Wasn't around much on Friday to watch trades going through but it looks to me as if all trades at 1.01p and above were buys. 1.00p trades and below were sells.

Can't even see the 400k trades you mention so can offer no opinion on them.

I see Feedback have an updated Governance charter since last Wednesday.

[ged5] 03/11/2019 10:30

Correct. It's there in black and white note 3e page 28:-

Following this fundraise the directors updated and reviewed the Group’s business plan and cash flow forecasts and consider that the Group and the Company will have adequate cash resources for at least the next twelve months to 31 October 2020, from existing cash balances.

Just in case we forget what the money is to be used for:-

These cash balances will be used to provide working capital, enable continued product development and international expansion.